The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Motley Rice LLC and other lead firms recently convened at the Philadelphia Federal Courthouse during a day-long science-based ...

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

U.S. drugmaker Eli Lilly on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective ...

Aronne, MD, of Weill Cornell Medicine in New York City, made a compelling case that the next generation of obesity ...